US FDA approves Johnson & Johnson's pill for psoriasis
Digest more
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis (PsA). | After ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results